Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. children and adolescents
Show results for
Products
Services
Applications

Companies

News
Articles
Videos

Refine by
Date

  • Older

Children And Adolescents Articles & Analysis

22 news found

New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA

New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA

Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions than any other NOAC: The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors The treatment of pulmonary embolism (PE) in adults The treatment of deep vein thrombosis (DVT) in adults The prevention of recurrent PE and/or DVT in ...

ByBayer AG


Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

In the U.S., approximately 6.4 million children and adolescents (11 percent) aged under the age of 18 have been diagnosed with ADHD. ...

ByCingulate


Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

About Attention Deficit/Hyperactivity Disorder (ADHD) Attention Deficit/Hyperactivity Disorder (ADHD) is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The condition is marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In the ...

ByCingulate


Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update

Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update

” In addition, our CTx-1301 Phase 3 fixed-dose pediatric and adolescent safety and efficacy study is now expected to commence in mid-2023 after the final two dosage strengths for this study are completed by Societal CDMO. ...

ByCingulate


Rivaroxaban (Xarelto) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation

Rivaroxaban (Xarelto) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation

Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions than any other NOAC: The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors The treatment of pulmonary embolism (PE) in adults The treatment of deep vein thrombosis (DVT) in adults The prevention of recurrent PE and/or DVT in ...

ByBayer AG


Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

Oral Podium Presentation Details Title: Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017) Date: Tuesday, May 31, 2022 Time: 4:20 p.m. ...

ByZynerba Pharmaceuticals, Inc.


Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

Presented data at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting in April and the 2022 International Society for Autism Research (INSAR) Annual Meeting in May demonstrating that in the long-term safety and efficacy study of Zygel in children and adolescents with FXS, improvement was seen in Social Avoidance in the full population, with the ...

ByZynerba Pharmaceuticals, Inc.


Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

The presentation titled, “Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017),” includes data from 240 patients and demonstrates the long-term safety and efficacy of Zygel in children and adolescents with FXS. ...

ByZynerba Pharmaceuticals, Inc.


Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting

Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting

Oral Podium Presentation Details Title: Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017) Date: Thursday, May 12, 2022 Time: 2:30 p.m. - 3:30 p.m. ...

ByZynerba Pharmaceuticals, Inc.


Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting

The poster titled, “Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017),” shows that in the ongoing long-term safety and efficacy study of Zygel in children and adolescents with FXS, Zygel was well-tolerated with long-term ...

ByZynerba Pharmaceuticals, Inc.


Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting

Poster Presentation Details Title: Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017) Date: Friday, April 29, 2022 Time: 5:00 p.m. - 7:00 p.m. ...

ByZynerba Pharmaceuticals, Inc.


U.S. FDA approves Xarelto to treat venous thromboembolism (VTE) and to prevent VTE in children

U.S. FDA approves Xarelto to treat venous thromboembolism (VTE) and to prevent VTE in children

Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable ...

ByBayer AG


Bayer extends clinical development program for finerenone with Phase III study in children and adolescents with chronic kidney disease

Bayer extends clinical development program for finerenone with Phase III study in children and adolescents with chronic kidney disease

“If successful, insights from this study could be of great significance to children living with chronic kidney disease and their families.” Proteinuria is an important modifiable risk factor for CKD progression in children. ...

ByBayer AG


Study Compares Nerivio® to Standard Care Medications for Acute Treatment of Migraine in Adolescents

Study Compares Nerivio® to Standard Care Medications for Acute Treatment of Migraine in Adolescents

"To my knowledge, this is the first study that directly compared remote electrical neuromodulation and standard-care treatment options in adolescents," said Andrew D. Hershey, MD, PhD, co-director of the Headache Center and the endowed chair and director of the Division of Neurology at Cincinnati Children's Hospital Medical Center, who was the primary ...

ByTheranica Bio-Electronics Ltd.


Profound Medical Receives FDA HDE Approval for Sonalleve

Profound Medical Receives FDA HDE Approval for Sonalleve

Osteoid osteoma is a non-cancerous bone tumor that occurs most often in the long bones of the leg, such as the femur and tibia, of young children and adolescents. An osteoid osteoma causes a dull, aching pain that is moderate in intensity, but can worsen and become severe, especially at night. ...

ByProfound Medical Corp.


Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases

Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases

Food and Drug Administration (FDA) for their lead prevention program and completed a Phase 1b “first in human” safety trial in adults, adolescents and children, recently scaling its manufacturing to support phase 2 studies. ...

BySiolta Therapeutics


Breakthrough in the global battle against polio: AJ Vaccines granted WHO prequalification for new polio vaccine

Breakthrough in the global battle against polio: AJ Vaccines granted WHO prequalification for new polio vaccine

The new vaccine will play a key role in the Global Polio Eradication Initiative (GPEI) The new Inactivated Polio Vaccine, Picovax®, is indicated for active immunization against poliomyelitis by primary vaccination of infants from the age of six weeks, and for revaccination of infants, children and adolescents. The dose sparing IPV is shown to provide ...

ByAJ Vaccines A/S


AJ Vaccines will contribute to global polio eradication with its innovative vaccine Picovax®

AJ Vaccines will contribute to global polio eradication with its innovative vaccine Picovax®

Picovax® provides active immunization against poliomyelitis by primary vaccination in infants from the age of 6 weeks and for revaccination of infants, children, adolescents and adults. Picovax® vaccine is based on a proprietary formulation technology that allows a lower dose of active substances, it is a well-tolerated and non-inferior alternative to ...

ByAJ Vaccines A/S


Health of vulnerable people exposed to noise is under-researched

Health of vulnerable people exposed to noise is under-researched

This study reviewed 62 papers, published from April 2006 to April 2011, which included the impact of environmental noise on the health of vulnerable people, including primary school children, young adolescents, preschool children, the elderly, and children with autism, asthma and attention deficit hyperactivity disorder. ...

ByEuropean Commission, Environment DG


Nearly 26 Million Americans Continue to Live with Asthma, EPA says

” Asthma is a national epidemic, affecting nearly 26 million people, including seven million children and disproportionally affecting low income and minority communities. ...

ByUS EPA - Environmental Protection Agency

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT